Anzeige
Erschienen in:
28.09.2022 | Original Article
Urine Calcium–Creatinine Ratio in Prediction of Pre-eclampsia
Erschienen in: The Journal of Obstetrics and Gynecology of India | Ausgabe 1/2023
Einloggen, um Zugang zu erhaltenAbstract
Background
Hypertensive disorders of pregnancy are first identified during pregnancy (gestational hypertension, pre-eclampsia, eclampsia, and HELLP syndrome) or may present as a complication of previously existing disease (chronic hypertension, renal disease, and systemic disease). These hypertensive disorders complicate the pregnancy, leading to significant maternal and perinatal morbidity and mortality, especially in low- and middle-income countries (Chappell in Lancet 398(10297):341–354, 2021). These hypertensive disorders are about 5–10% of all pregnancies.
Methods
This is a single institutional study, which was conducted among 100 normotensive asymptomatic antenatal women at, 20–28 weeks of gestation attending our OPD. Voluntary participants were selected based on inclusion and exclusion criteria. Spot urine sample was taken for estimation of UCCR by an enzymatic colorimetric method. These patients were followed up throughout the pregnancy and monitored for the development of pre-eclampsia. UCCR is compared in both groups. Pre-eclampsia women were further followed up to observe the perinatal outcomes.
Results
Among 100 antenatal women, 25 of them developed pre-eclampsia. UCCR of < 0.04 was considered as cutoff and compared between pre-eclampsia and normotensive women. This ratio yielded a sensitivity of 61.54%, specificity 87.84%, positive predictive value 64%, and negative predictive value of 86.67%. It was also observed that primigravida had more sensitivity (83.3%) and specificity (91.7%) in predicting pre-eclampsia compared to multigravida. The mean and median UCCR among pre-eclamptic women was significantly low (0.062 ± 0.076, 0.03) compared to normotensive women (0.15 ± 0.115, 0.12) with a p value of < 0.001.
Conclusions
Spot UCCR is a good predictor of pre-eclampsia in primigravida women and can be considered as a routine screening test at 20–28 weeks of gestation during regular antenatal visits.